Given that scenario, I would think many long-term shareholders would like to see the pps trickle down even further in order to load up for the eventual FDA approval?
I'm not sure about Bavi NSCLC FDA approval before the next ASM. However, we may have data from the trial making it clear that such approval will happen. Good enough to get a buyout we can live with.